Zyneyro

Executive Summary

Zyneyro is a Danish biotechnology company founded in 2020, leveraging over 20 years of pioneering research from the University of Copenhagen to develop novel therapies for chronic pain. Its lead program, ZYNPN, is a synthetic peptide designed to target maladaptive neural plasticity in neuropathic pain, aiming to avoid the side effects and addiction risks associated with current treatments. The company operates at the intersection of neuroscience and digital health, though its primary focus remains on peptide-based therapeutics. As a private, early-stage venture, Zyneyro has yet to disclose funding rounds or valuation, indicating it may be in preclinical or early clinical development. The company's innovative approach addresses a significant unmet need in chronic pain management, where existing options often lead to dependency or inadequate relief. However, Zyneyro faces typical early-stage risks, including the need for substantial capital to advance ZYNPN through preclinical studies and into clinical trials. The lack of disclosed financial backing or partnerships suggests the company may be seeking Series A financing. Success will depend on generating compelling preclinical data and securing strategic alliances. With a focused pipeline and a strong scientific foundation, Zyneyro represents a high-risk, high-reward opportunity in the pain therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data readout for ZYNPN60% success
• Q4 2026Series A financing round50% success
• H1 2027Partnership or licensing deal for ZYNPN40% success